Humanized monoclonal antibody armanezumab specific to N-terminus of pathological tau: characterization and therapeutic potency
The experience from clinical trials indicates that anti-Aβ immunotherapy could be effective in early/pre-clinical stages of AD, whereas at the late stages promoting the clearing of Aβ alone may be insufficient...